Neurology Central

Depatux-M fails to meet primary endpoint in late-stage trial for newly diagnosed glioblastoma


AbbVie (IL, USA) has announced that it halted enrolment in all studies of depatuxizumab mafodotin (Depatux-M, previously known as ABT-414) after an interim analysis of a Phase III trial (INTELLANCE-1) demonstrated that the drug failed to prolong overall survival compared to placebo in individuals with newly diagnosed glioblastoma whose tumors have EGFR amplification.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.